8-K: Galectin Therapeutics Announces Positive Top-Line Data from NAVIGATE Trial and Plans for FDA Engagement

Galectin Therapeutics reports favorable clinical effects of belapectin in patients with cirrhosis caused by MASH, demonstrating a significant reduction in new varices in the NAVIGATE trial.

Summary

• Galectin Therapeutics presented data from its NAVIGATE trial, showcasing positive results for belapectin in treating cirrhosis caused by MASH with portal hypertension.
• The trial demonstrated a 49% outperformance of the 2mg drug arm compared to placebo in the per protocol population, which included patients completing the full 18-month therapy.
• In the intent-to-treat (ITT) population, a 43.2% reduction in the incidence of new varices was observed, while the per-protocol population showed a 48.9% reduction.
• Favorable results were also noted in non-invasive biomarkers of fibrosis, such as liver stiffness measure on FibroScan and ELF score.
• The safety profile of belapectin remained favorable, with no drug-related serious adverse events reported.
• The company plans to complete further data analysis, including 36-month data and specialized biomarker analyses, by the end of the current quarter.
• Galectin intends to engage with the FDA to discuss the next steps for belapectin's development program in the first half of 2025.
• The company has initiated discussions with potential pharma partners regarding the data and development plans.

Sentiment

Score: 8

Explanation: The document expresses a highly positive sentiment due to the favorable results from the NAVIGATE trial, the anticipation of FDA engagement, and the potential for partnerships. The management's comments are optimistic, and the company believes its results are groundbreaking.

Positives

• Belapectin demonstrated a favorable clinical effect in patients with cirrhosis caused by MASH with portal hypertension.
• The NAVIGATE trial achieved its primary endpoint of reducing the incidence of new varices.
• The safety profile of belapectin remains favorable.
• Key Opinion Leaders have expressed positive reactions to the results.
• The company plans to meet with the FDA to discuss the results of NAVIGATE and clarify the next steps in the development of belapectin.

Risks

• The company's future success depends on the FDA's acceptance of the NAVIGATE trial results.
• Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.
• Global factors such as coronavirus may continue to impact NASH patient populations around the globe and slow trial enrollment and prolong the duration of the trial and significantly impact associated costs.

Future Outlook

Galectin Therapeutics anticipates a meeting with the FDA in the first half of 2025 to discuss the NAVIGATE trial results and determine the next steps for belapectin's development. The company also plans to present additional results around the end of the current quarter and is actively seeking potential pharma partners.

Management Comments

• '2024 was a monumental year for Galectin Therapeutics, and I anticipate that 2025 will be even more important for the Company and our development program.'
• 'We believe that our results are groundbreaking.'
• 'For the first time in history, a drug candidate demonstrated a favorable clinical effect in patients with cirrhosis caused by MASH that has progressed to include portal hypertension.'
• 'We remain very encouraged by the trial data from NAVIGATE thus far and eagerly await additional results which we expect to present around the end of this quarter.'
• 'We believe the results are compelling, and no other company, to our knowledge, has shown any data similar to what we have demonstrated with belapectin in MASH cirrhosis.'

Industry Context

The announcement addresses a significant unmet need in the treatment of MASH cirrhosis and portal hypertension, positioning Galectin Therapeutics as a potential leader in this therapeutic area. The company believes that no other company has shown similar data with belapectin in MASH cirrhosis.

Comparison to Industry Standards

• The document mentions that the definition of the per protocol population aligns with other MASH trials where similar criteria are used for biopsy based primary end points.
• The pre-specified magnitudes of changes in Liver stiffness measure and ELF were based on previous studies where they correlated with adverse outcomes including complications of cirrhosis.

Stakeholder Impact

• Shareholders may benefit from the positive trial results and potential for future partnerships.
• Patients with MASH cirrhosis and portal hypertension may have a new treatment option available.
• The Galectin team is recognized for their dedication and hard work in completing the NAVIGATE trial.

Next Steps

• Complete the evaluation of all 18-month results, the available 36-month data set, and additional specialized biomarkers of fibrosis analyses by the end of this quarter.
• Engage with the FDA to discuss the next steps for the program in the first half of 2025.
• Continue to analyze data as it becomes available.
• Talk to potential pharma partners about the data and development plans.

Key Dates

Keywords

belapectin, MASH cirrhosis, NAVIGATE trial, portal hypertension, Galectin Therapeutics, varices, FDA, liver disease